Cloudbyz

JUNE 11, 2023

Decentralized Clinical Trials (DCTs), also known as remote or virtual trials, are an innovative approach to executing clinical trials that permit remote participation, execution, and data accumulation. Participant Interaction: Traditional trials necessitate face-to-face interactions between participants and investigators.

Clinical Trials 74

Clinical Trials Clinical Trials Trials Compliance 74

The Pharma Data

JANUARY 21, 2021

And a new study suggests more is better, with well-being rising as earnings grow. “Having more money gives people a greater sense of control over life,” said study author Matthew Killingsworth. But this study appears to disagree. 26 issue of the Proceedings of the National Academy of Sciences. THURSDAY, Jan.

Research 52

Research 52

XTalks

NOVEMBER 9, 2020

AstraZeneca was forced to halt its Phase III trial temporarily in September as one of the trial participants developed a rare, but serious, reaction following receipt of its vaccine. The WHO study; however, has been criticized for being poorly designed, which makes any conclusions reached questionable.

Vaccination 105

Vaccination Vaccine Development Drugs 105

The Pharma Data

OCTOBER 19, 2020

“People with bipolar disorder have significant mood swings, from periods of depression to mania,” explained study author David Miklowitz, a professor of psychiatry with UCLA’s David Geffen School of Medicine’s Semel Institute for Neuroscience and Behavior. MONDAY, Oct.

Medicine 52

Medicine Development Drugs Research 52

The Pharma Data

APRIL 29, 2022

(NYSE: PFE) today shared top-line results from the Phase 2/3 EPIC-PEP ( E valuation of P rotease I nhibition for C OVID-19 in P ost- E xposure P rophylaxis) study evaluating PAXLOVID™ (nirmatrelvir [PF-07321332] tablets and ritonavir tablets) for post-exposure prophylactic use. FDA Emergency Use Authorization Statement.

HR 52

HR Drugs Trials Development 52

The Pharma Data

JANUARY 21, 2021

NASDAQ: REGN) and Society for Science (the Society) today named 40 finalists in the Regeneron Science Talent Search 2021, the nation’s oldest and most prestigious science and math competition for high school seniors. ” Regeneron Science Talent Search 2021 Fast Facts. Regeneron Pharmaceuticals, Inc.

Scientist 40

Scientist Engineer Medicine Bioinformatics 40

STAT News

MARCH 6, 2023

Cambridge-based Moderna recently reported encouraging results from a study of another type of personalized cancer vaccine it developed with the pharmaceutical giant Merck; it uses messenger RNA technology to target advanced melanoma. Therapeutic vaccines represent the next frontier in cancer medicine.

Vaccination 98

Vaccination Vaccine Drugs Clinical Trials 98

The Pharma Data

FEBRUARY 22, 2021

Second Phase 3 Induction Study Confirms Upadacitinib (RINVOQ ) Improved Clinical, Endoscopic and Histologic Outcomes in Ulcerative Colitis Patients. 1 In the study, 33 percent of patients receiving upadacitinib achieved clinical remission (per Adapted Mayo Score) at week 8 compared to 4 percent of patients receiving placebo (p<0.001).

Medicine 52

Medicine Development Drugs Trials 52

The Pharma Data

JUNE 18, 2021

1 This is the first presentation of data from these two studies, ADVANCE and MOTIVATE, following the announcement of top-line data earlier this year. The ADVANCE study included patients with past intolerance or inadequate response to conventional therapy (non-bio-IR) and/or biologic therapy (bio-IR). NORTH CHICAGO, Ill. , Population.

Clinical Trials 40

Clinical Trials Clinical Trials Trials Development 40

The Pharma Data

DECEMBER 23, 2020

INO-4800, beyond being safe and tolerable, is stable at room temperature for more than a year, at 37 o C (98.6 The participants were enrolled into 1.0 mg dose cohorts; each participant received two doses of INO-4800 four weeks apart. . The participants were enrolled into 1.0 mg and 2.0

DNA 40

DNA Vaccination Vaccine Immune Response 40

The Pharma Data

JUNE 18, 2021

In this study, a higher proportion of patients treated with RINVOQ 15 mg achieved and maintained clinical remission and low disease activity compared to those treated with HUMIRA, through three years. ” SELECT-COMPARE Results at Three Years. RINVOQ 15 mg plus MTX. HUMIRA 40 mg EOW plus MTX. Clinical remission per DAS28-CRP<2.6

Trials 40

Trials Production Clinical Trials Clinical Trials 40

XTalks

JANUARY 31, 2022

Pfizer and BioNTech have started to enroll participants in a study that will evaluate the new version of their COVID-19 vaccine that targets the omicron variant of SARS-CoV-2. Moderna anticipates enrolling about 300 participants into each of the two cohorts of the study, which will be conducted at up to 24 sites in the US.

Vaccination 98

Vaccination Vaccine Trials Antibody 98

The Pharma Data

APRIL 23, 2021

The European Medicine Agency’s approval of dostarlimab is based on results from the multi-cohort GARNET study, which included women with recurrent or advanced dMMR/MSI-H endometrial cancer who progressed on or after a platinum-based chemotherapy regimen in cohort A1 (n=108 evaluable for efficacy). and 90.9% (95% CI; 73.7, 97.1), respectively.

Antibody 52

Antibody Hormones Licensing Licensing 52

WCG Clinical

MAY 24, 2023

A Broken Status Quo Sponsors are stuck: The cycle times associated with study startup, including site identification and activation, have changed little over the past 20 years. Even though 89% of studies meet enrollment goals, sponsors are often forced to extend—even double—the original timeline due to poor enrollment.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Development 52

The Pharma Data

OCTOBER 28, 2020

had one or more underlying risk factors for severe COVID-19, including obesity (37%). In total, 47% of participants were male and 53% were female. . Approximately 50% of patients were Hispanic, 9% were African American and 60.5% On average, patients were 42.2 years of age.

Antibody 40

Antibody Trials Production Clinical Trials 40

XTalks

DECEMBER 7, 2020

Among the total cohort involving 11,363 participants, the vaccine had a 90 percent efficacy rate among those who received a half dose of the vaccine followed by a full dose a month later, while among those who received two full doses at least one month apart, the vaccine was still 62 percent effective against the virus.

Vaccination 52

Vaccination Vaccine Development Drugs 52

The Pharma Data

OCTOBER 12, 2021

The trial recorded 18 events in the AZD7442 arm (18/407) and 37 in the placebo arm (37/415). 903 participants were randomised (1:1) to receive either AZD7442 (n = 452) or saline placebo (n = 451), administered in two separate, sequential IM injections. Approximately 13% of participants were 65 years and over.

Trials 52

Trials Development Antibody Radiology 52

The Pharma Data

NOVEMBER 30, 2020

(Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that the primary efficacy analysis of the Phase 3 study of mRNA-1273 conducted on 196 cases confirms the high efficacy observed at the first interim analysis.

Vaccination 52

Vaccination Vaccine Medicine Clinical Trials 52

XTalks

FEBRUARY 5, 2024

In the dynamic landscape of oncology therapeutics, understanding the trends and performances of leading drugs is crucial for stakeholders across the healthcare and life sciences sectors. In the studies, a combination of Keytruda and chemotherapy led to nearly 20 percent of patients with NSCLC surviving for five years.

FDA Approval 101

FDA Approval Drugs Sales Development 101

The Pharma Data

JANUARY 21, 2021

.” The approval of CABENUVA is based on the pivotal Phase 3 ATLAS (Antiretroviral Therapy as Long-Acting Suppression) and FLAIR (First Long-Acting Injectable Regimen) studies that included more than 1,100 patients from 16 countries, including the U.S. 50 c/mL at Week 48 (Treatment Difference 0.7%; 95% CI: -1.2%, 2.5%).

FDA Approval 52

FDA Approval RNA Drugs Containment 52

Drug Discovery World

JANUARY 26, 2023

Colin Terry, European Life Sciences R&D leader at Deloitte, explains: “Revitalising today’s clinical trials processes and operations will drastically improve trial efficiency, enhance science-based decisions, and expand collective health equity.

Development 98

Development Drugs Clinical Trials Clinical Trials 98

The Pharma Data

JULY 12, 2021

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the presentation of data from the company’s HIV clinical development program at the 11th International AIDS Society Conference on HIV Science (IAS 2021) from July 18-21. E-poster Presentation PEC307. Abstract 2322. Parkin et al. E-poster Presentation PEB168.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Clinical Development 52

The Pharma Data

AUGUST 22, 2021

The trial included 5,197 participants in a 2:1 randomisation AZD7442 to placebo. The primary analysis was based on 5,172 participants who did not have SARS-CoV-2 infection at baseline. More than 75% of participants had co-morbidities, which include conditions that have been reported to cause a reduced immune response to vaccination.

Trials 52

Trials Antibody Vaccination Vaccine 52

The Pharma Data

JULY 8, 2021

Patients who participated in the NAVIGATOR and SOURCE trials were eligible to continue in DESTINATION, a Phase 3 extension trial assessing long-term safety and efficacy.(23). We lead with science through discovery research that is disease-agnostic and biology-first, modality-second. 2016;116:37-42. About Tezepelumab.

Allergies 52

Allergies Trials In-Vivo Medicine 52

XTalks

FEBRUARY 5, 2024

In the dynamic landscape of oncology therapeutics, understanding the trends and performances of leading drugs is crucial for stakeholders across the healthcare and life sciences sectors. In the studies, a combination of Keytruda and chemotherapy led to nearly 20 percent of patients with NSCLC surviving for five years.

FDA Approval 52

FDA Approval Drugs Sales Development 52

The Pharma Data

APRIL 26, 2021

Adakveo sales reached USD 37 million. 177 Lu-PSMA-617 Ph3 VISION study met both primary endpoints in patients with prostate cancer. USD 37 million, +148% cc) US launch continued to progress well, with approximately 800 accounts purchasing Adakveo to date. Ph3 study program underway. Kesimpta sales reached USD 50 million.

Sales 40

Sales Medicine Production Manufacturing 40

The Pharma Data

MAY 13, 2021

Some of our testimonials are provided by customers who have received promotional offers in exchange for their participation. Critical Reviews in Food Science and Nutrition. Proceedings of the National Academy of Sciences of the United States of America. Curr Opin Clin Nutr Metab Care. 2017 Jul;20(4):279- 285. DOI: 10.1097/MCO.0000000000000377.

Insulin 52

Insulin Production Hormones Medicine 52

The Pharma Data

OCTOBER 6, 2021

We look forward to participating AZD7442 data for the treatment of COVID-19 thereafter this vintage.” 9) AZD7442 is being studied in a comprehensive clinical trial programme for both forestallment and treatment of COVID-19 in over parties. 2018; 37 (9) 886-892. Pediatr Infect DisJ. Wang L et al. 2021 Jul 1. Front Immunol.

Antibody 52

Antibody In-Vitro Trials Vaccination 52

XTalks

SEPTEMBER 14, 2020

Already in Phase III clinical trials, interim results from their Phase I/III COV001 trial showed that neutralizing antibody responses against SARS-CoV-2 were detected in 91 percent of participants after a single dose of the vaccine, and in all participants after a booster dose. times higher than those from previously infected patients.

Vaccination 92

Vaccination Vaccine Antibody Life Science 92